Dr Philip Camilleri
MRCP MD FRCR
Philip Camilleri graduated in Medicine and Surgery in 1995 from the University of Malta. He commenced specialist training in Oxford in 1999, having successfully obtained Membership of the Royal College of Physicians (London). Subsequently he achieved Fellowship of the Royal College of Radiologists (UK) in 2003. In 2005 he gained entry into the specialist register in the United Kingdom.
Between 2006 and 2012 he worked as a consultant clinical oncologist at Northampton General Hospital, forming an integral part of the urological and lung cancer services.
He helped to deliver the Low Dose Rate Brachytherapy Service for prostate cancer gaining valuable experience.
He also helped to set up a number of services there including:
- Intensity Modulated Radiotherapy for prostate cancer
- A pilot gold fiducial marker service for prostate cancer
- High Dose Rate brachytherapy for prostate cancer
- Stereotactic Body Radiotherapy for lung cancer.
In 2012 he obtained a consultant post in Oxford, where he has been involved in a number of further service delivery projects including:
- Setting up and delivering the Oxford Low Dose Rate brachytherapy service.
- Helping to roll out Intensity Modulated Radiotherapy for prostate cancer which includes treating the prostate alone, the prostate bed after surgery and the pelvic lymph nodes.
- Setting up a nurse led prostate cancer follow up service
- Setting up Radium 223 isotope injection service for prostate cancer
- Developing Stereotactic Body Radiotherapy for prostate cancer.
Philip Camilleri is married with three young children. He lives in Oxfordshire and enjoys sport including tennis and cycling.
He is fluent in English, Italian and Maltese and can converse in French.
Dr Camilleri provides both radiotherapy and chemotherapy options for patients with prostate and bladder cancer. He also provides radiotherapy expertise for testicular and bladder patients
- Intensity modulated radiotherapy (IMRT) with image guided radiotherapy (IGRT) for low, intermediate or high risk disease
- IMRT and IGRT to the prostate and pelvic lymph nodes for high risk disease.
- Low Dose Rate brachytherapy for low and intermediate risk disease.
- Palliative radiotherapy for symptom control
- Hormone therapy with oral and injectable anti-androgens
- Chemotherapy with Docetaxel and Cabazitaxel
- Novel anti-androgen therapy with Abiraterone (Zytiga) and Enzalutamide
- Supportive therapy with Denosumab and Zometa for bone health
- Isotope therapy with Radium 223 for metastatic cancer support.